Cell therapy for recurrent brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental cell therapy (CHT101) for people with certain aggressive brain tumors. It aims to see if the therapy is safe and may help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called high-grade glioma or primary central nervous system lymphoma.
- Your tumor must test positive for a protein called CD70.
- An MRI must show at least one measurable tumor in the brain.
- You should be able to care for yourself and do daily tasks (score of 70 or higher on a standard scale).
- You must not have had CAR-T therapy or other cell/gene therapies before.
- You cannot have certain conditions like brainstem recurrence, spinal spread, or other recent cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called CHT101 for blood cancers that have come back or stopped responding to other treatments. It targets a specific protein (CD70) on cancer cells, and the goal is to see if it can shrink or control the cancer.
This trial is testing a new type of cell therapy called CAR-T that targets a marker (B7-H3) on brain tumor cells. It is for people with grade 4 gliomas that have returned after standard treatment, and it aims to see if this treatment can help control the tumor.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Hear when a new Brain (Nervous System) Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.